Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance.
about
K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanismIn vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitroCharacterization of human immunodeficiency virus type 1 strains resistant to the non-nucleoside reverse transcriptase inhibitor RD4-2217Fitness ranking of individual mutants drives patterns of epistatic interactions in HIV-1A Cinnamon-Derived Procyanidin Compound Displays Anti-HIV-1 Activity by Blocking Heparan Sulfate- and Co-Receptor- Binding Sites on gp120 and Reverses T Cell Exhaustion via Impeding Tim-3 and PD-1 UpregulationPurifying selection masks the mutational flexibility of HIV-1 reverse transcriptase.Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha.Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assayRelative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system.Impaired replication capacity of acute/early viruses in persons who become HIV controllers.9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPAMolecular epidemiology of HIV type 1 in newly diagnosed patients in southern Spain.Relationship of injection drug use, antiretroviral therapy resistance, and genetic diversity in the HIV-1 pol geneVirulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure.Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation.Frequency of mutations conferring resistance to nucleoside reverse transcriptase inhibitors in human immunodeficiency virus type 1-infected patients in Korea.Structural and molecular interactions of CCR5 inhibitors with CCR5.The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains.The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.Population-based human immunodeficiency virus 1 drug resistance profiles among individuals who experienced virological failure to first-line antiretroviral therapy in Henan, China during 2010-2011Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy.HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors.Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1.Clinical significance of human immunodeficiency virus type 1 replication fitness.Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20Thymidine analogue resistance suppression by V75I of HIV-1 reverse transcriptase: effects of substituting valine 75 on stavudine excision and discrimination.Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.Long-term benefit of genotypic-guided therapy and prevalence of multinucleoside resistance in an Italian group of antiretroviral multiexperienced patients.Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.Estimating relative fitness in viral competition experiments.Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adultsSynthesis and biological evaluation of selective CXCR4 antagonists containing alkene dipeptide isosteres.Structural Insights into HIV Reverse Transcriptase Mutations Q151M and Q151M Complex That Confer Multinucleoside Drug Resistance.Gln145Met/Leu changes in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nucleoside and nonnucleoside analogs and impair virus replication.Design, efficient synthesis, and anti-HIV activity of 4'-C-cyano- and 4'-C-ethynyl-2'-deoxy purine nucleosides.Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations.
P2860
Q21135752-CC389D78-C7E2-4F9C-9A1F-3CDA72632595Q28343615-14A809EB-18E3-4205-B63B-E1AEAA583E78Q28362567-DDC9731C-03A1-48A8-BB73-F57FA7430101Q28378595-1198A531-09C0-4A69-9615-C1521336303FQ28477614-9407AA0C-ACFF-472A-A449-5B9504043E76Q28553032-09490ECA-E66B-4A1E-AB03-10461983CD49Q33199293-7261E6E5-4319-4BAE-86B3-18181C83B593Q33797534-DE28703C-CC98-4C17-A33F-3BBEFD96CFBEQ33811164-E46C7447-24C3-4F39-B70F-747951909588Q33814927-571EEA5F-224F-427D-9F34-B0686A8120C9Q33826453-A9D0B68C-D40C-44BB-96F3-278938D60A74Q33907525-ABD0BF1E-D37E-403A-8893-AFD95B64671EQ33963989-CE746BA5-38D6-421D-B686-8D0DD8AC00C3Q33976617-6BAF8B0B-611C-407A-8DC4-1634C0F42D18Q34080813-5F2EF601-0461-43E1-B60B-9CE26525CB65Q34118276-3A057FB7-2F33-4383-9562-6E0368D1FD82Q34339657-545D09EA-6BA5-4BD8-A8F4-8FFBCAE143F3Q34342200-2005161B-7393-4D78-99DE-ED482B112397Q34348774-D421798A-58AB-4FD9-A90E-AD33D8609D95Q34454702-E68217C6-B245-485B-8879-C644BB98220AQ34494226-6D3E9D12-2FCA-43BC-85AF-2A3F81C41EF0Q35042225-94167868-B915-445A-86AC-B86BAD74F0C0Q35784897-266ABA7D-3F8E-4D98-8DB3-C926443A3564Q35789353-DB47B073-4C78-479F-AC48-5D16BD7A029FQ35842525-3BEBD8F7-85FE-44CF-A9E0-EFF6DBAF3372Q35943486-C5EEC2CE-E840-4BD4-BE21-2F19BFA61ECCQ36414526-A6819CE7-F0E6-47FA-85C1-106CD96517FAQ36969857-1C97AC7E-7D5F-451F-A157-78CA7C783E05Q37099189-A3F3C65B-BF23-4FD5-AA78-638E868E2E33Q37432131-EC81700F-1051-4C90-9E75-3F8CC33D7827Q37742855-CB489721-962B-4238-807A-10D2C3A952DEQ39375499-BCCBB5CC-067F-4D7A-A12C-2BB1171CBB56Q39550343-175B8B6F-8A93-4D0B-9B12-77F9FDF05E99Q39597718-8B79E0BB-4F32-4B2B-A09A-14B61FC89D28Q39685276-52A5FFEF-0A17-40C4-97DF-80F5DD804056Q39749640-2474A46E-D184-4B15-8C3D-7389A3FC32D2Q40249141-3FE31A80-60B0-40E5-BA06-93C294405DD5Q40425060-0163A03B-6DB0-4BBA-8698-A6D9DF4F4FD8Q40544786-6E9F832C-7765-4948-89D5-19DF43DCA467Q40688262-B2B0B259-F68D-4C74-BE1D-9494703B3146
P2860
Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance.
description
1998 nî lūn-bûn
@nan
1998 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Altered drug sensitivity, fitn ...... -dideoxynucleoside resistance.
@ast
Altered drug sensitivity, fitn ...... -dideoxynucleoside resistance.
@en
Altered drug sensitivity, fitn ...... -dideoxynucleoside resistance.
@nl
type
label
Altered drug sensitivity, fitn ...... -dideoxynucleoside resistance.
@ast
Altered drug sensitivity, fitn ...... -dideoxynucleoside resistance.
@en
Altered drug sensitivity, fitn ...... -dideoxynucleoside resistance.
@nl
prefLabel
Altered drug sensitivity, fitn ...... -dideoxynucleoside resistance.
@ast
Altered drug sensitivity, fitn ...... -dideoxynucleoside resistance.
@en
Altered drug sensitivity, fitn ...... -dideoxynucleoside resistance.
@nl
P2093
P356
P1476
Altered drug sensitivity, fitn ...... -dideoxynucleoside resistance.
@en
P2093
P304
P356
10.1086/515282
P407
P577
1998-05-01T00:00:00Z